Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
Paul M O'Byrne, Eugene R Bleecker, Eric D Bateman, William W Busse, Ashley Woodcock, Richard Forth, William T Toler, Loretta Jacques, Jan Lötvall, Paul M O'Byrne, Eugene R Bleecker, Eric D Bateman, William W Busse, Ashley Woodcock, Richard Forth, William T Toler, Loretta Jacques, Jan Lötvall
Abstract
The inhaled corticosteroid fluticasone furoate (FF) and the long-acting β₂ agonist vilanterol (VI) are in development as a combined once-daily therapy for asthma and chronic obstructive pulmonary disease. Our study objectives were to compare the efficacy and safety of once-daily FF/VI with FF alone and twice-daily fluticasone propionate (FP) in patients aged ≥12 years with moderate-to-severe persistent asthma. Patients (n=586) received FF/VI 200/25 μg or FF 200 μg once-daily (evening dosing), or FP 500 μg twice-daily for 24 weeks. Co-primary end-points were change from baseline in trough forced expiratory volume in 1 s (FEV₁) weighted mean (wm) 0-24 h serial FEV1. Secondary end-points included change from baseline in percentage of rescue-free 24-h periods, percentage of symptom-free 24-h periods and total Asthma Quality of Life Questionnaire (AQLQ). Safety assessments included adverse events, 24-h urinary cortisol excretion, vital signs and ECG. FF/VI significantly improved trough FEV1 and wmFEV₁ versus FF and FP. Significantly more rescue-free and symptom-free 24-h periods were reported with FF/VI versus FF. Treatment differences for AQLQ were not significant. Incidence of adverse events was similar across groups. No clinically significant differences were seen for 24-h urinary cortisol excretion, vital signs or ECG. FF/VI resulted in statistically greater improvements in lung function and symptomatic end-points versus FF, and was well tolerated in this asthma population.
Trial registration: ClinicalTrials.gov NCT01134042.
Conflict of interest statement
Conflict of interest: Disclosures can be found alongside the online version of this article at www.erj.ersjournals.com
Figures
References
- British Thoracic Society and Scottish Intercollegiate Guidelines Network British guideline on the management of asthma: a national clinical guideline. Thorax 2008; 63: Suppl. 4, iv1–iv121
- Global Initiative for Asthma Global Strategy for Asthma Management and Prevention, 2012. Date last updated: December, 2012. Date last accessed: October 9, 2013
- Fanta CH. Drug therapy: asthma. N Engl J Med 2009; 360: 1002–1014
- Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010; 10: 1.
- US prescribing information for veramyst (fluticasone furoate) nasal spray Indicated for treatment of symptoms of seasonal and perennial allergic rhinitis in adults and children ≥2 years. Date last updated: October, 2011. Date last accessed: October 9, 2013
- European Medicines Agency authorisation codes EU/1/07/434/001; EU/1/07/434/002; EU/1/07/434/003 Avamys (fluticasone furoate) indicated for the treatment of symptoms of allergic rhinitis: summary of product characteristics. Date last accessed: October 9, 2013
- Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem 2008; 51: 3349–3352
- Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007; 293: 660–667
- Bateman ED, Bleecker ER, Lötvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med 2012; 106: 642–650
- Bleecker ER, Bateman ED, Busse WW, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol 2012; 109: 353–358
- Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2012; 67: 35–41
- Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res 2011; 12: 160.
- Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting β2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010; 5: CD005535.
- Lötvall J, Bateman ED, Bleecker ER, et al. 24 h duration of the novel LABA vilanterol trifenatate in asthma patients treated with ICSs. Eur Respir J 2012; 40: 570–579
- O’Byrne PM, Bleecker ER, Bateman ED, et al. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma. Eur Respir J 2012; 40: Suppl. 56, S313
- National Institutes for Health Guidelines for the Diagnosis and Management of Asthma (EPR-3). Date last updated: August, 2007. Date last accessed: October 9, 2013
- World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Date last updated: 2008. Date last accessed: October 9, 2013
- International Conference on Harmonisation Tripartite Guideline Guidance for Good Clinical Practice E6 (R1). 1996. Date last accessed: October 9, 2013
- Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011; 128: 1185–1191
- Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 2002; 109: Suppl. 6, S554–S559
- Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–1310
- Ni Chroinin M, Greenstone I, Lasserson TJ, et al. Addition of inhaled long-acting β2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev 2009; 7: CD005307.
- Cloutier MM, Schatz M, Castro M, et al. Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol 2012; 129: S24–S33
Source: PubMed